Lisata Therapeutics, Inc. Common Stock (LSTA) is a publicly traded Healthcare sector company. As of November 9, 2026, LSTA trades at $1.09 with a market cap of $11.13M and a P/E ratio of -0.80. LSTA moved +5.83% today. Year to date, LSTA is -47.45%; over the trailing twelve months it is -56.17%. Its 52-week range spans $0.96 to $5.07. Rallies surfaces LSTA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Lisata subsidiary Marea's MAR001 meets primary endpoint in Phase 2b triglyceride trial: Marea Therapeutics, a Lisata Therapeutics subsidiary, met all objectives in Part A of its Phase 2b TYDAL-TIMI 78 trial of MAR001. Placebo-adjusted triglyceride reductions were 39.1% to 45.5% at Week 12 and were sustained through Week 24.
| Metric | Value |
|---|---|
| Price | $1.09 |
| Market Cap | $11.13M |
| P/E Ratio | -0.80 |
| EPS | $-1.91 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.07 |
| 52-Week Low | $0.96 |
| Volume | 85.14K |
| Avg Volume | 0 |
| Revenue (TTM) | $170.00K |
| Net Income | $-16.59M |
| Gross Margin | 0.00% |
LSTA analyst coverage data. Average price target: $0.00.